Six US IPOs were able to raise $970 million last week including two $330 million + deals. Three IPOs offered double-digit first-day pops, including e-commerce...read more
Portola Pharmaceuticals, which is developing a blood thinner and a novel reversal agent for acutely ill patients, raised $122 million in an upsized IPO by offering 8.4 million shares at $14.50, the midpoint of...read more
Deal flow picked up from already high levels, but returns were light in a ten-IPO week, just the second since 2007. Half of the week’s deals were from financial companies, while the largest was a $947 million offering from Quintiles Transnational (Q), a...read more
US IPO Recap: IPO market continues torrid pace with six pricings, 12 new filers
Six US IPOs were able to raise $970 million last week including two $330 million + deals. Three IPOs offered double-digit first-day pops, including e-commerce...read more
Portola Pharmaceuticals prices upsized IPO at $14.50, within the range
Portola Pharmaceuticals, which is developing a blood thinner and a novel reversal agent for acutely ill patients, raised $122 million in an upsized IPO by offering 8.4 million shares at $14.50, the midpoint of...read more
6 US IPOs planned for the week of May 20
The following IPOs are expected to price this week: Alcobra (ADHD), an Israeli drug company developing a non-stimulant ADHD treatment, plans to raise $25 million by...read more
US IPO Recap: Ten deals price, highest weekly total since 2010
Deal flow picked up from already high levels, but returns were light in a ten-IPO week, just the second since 2007. Half of the week’s deals were from financial companies, while the largest was a $947 million offering from Quintiles Transnational (Q), a...read more